Absci, a Vancouver, Wash.-based company that uses AI to develop drugs, is partnering with Memorial Sloan Kettering Cancer Center to create up to six novel cancer therapeutics using generative artificial intelligence.
The company and the New York-based cancer research center say they plan to combine Absci’s AI and wet lab technologies with Memorial Sloan Kettering’s oncology expertise to co-develop the therapeutics, and better understand the potential for AI to help in the fight against cancer.
MSK will identify cancer targets, and Absci will design antibodies to bind to those targets using artificial intelligence, according to a report by ZDNet, which said the partnership began with talks at the J.P. Morgan Healthcare conference in San Francisco in January.